|1.||Krishna, Murali C: 2 articles (12/2012 - 02/2002)|
|2.||Mitchell, James B: 2 articles (12/2012 - 02/2002)|
|3.||Davis, Ryan M: 1 article (12/2012)|
|4.||Matsumoto, Shingo: 1 article (12/2012)|
|5.||Hyodo, Fuminori: 1 article (12/2012)|
|6.||Hyodo, Emi: 1 article (12/2012)|
|7.||Dhimitruka, Ilirian: 1 article (09/2009)|
|8.||Marsh, Clay B: 1 article (09/2009)|
|9.||Bobko, Andrey A: 1 article (09/2009)|
|10.||Eubank, Timothy D: 1 article (09/2009)|
02/19/2002 - "OMRI experiments were performed on tumor-bearing mice (squamous cell carcinoma) by i.v. administration of the contrast agent Oxo63 (a highly derivatized triarylmethyl radical) at nontoxic doses in the range of 2-7 mmol/kg either as a bolus or as a continuous infusion. "
09/01/2009 - "Application of the TAM-H probe allows for EPR measurements in an extended range of oxygen pressures from atmospheric to 1 mm Hg, whereas the EPR spectrum linewidth of the popular TAM-based oxygen sensor Oxo63 is practically insensitive to oxygen partial pressures below 20 mm Hg. Enhanced sensitivity of the TAM-H probe relative to Oxo63 was demonstrated in the detection of oxygen consumption by Met-1 cancer cells. "
12/01/2012 - "To test this, the redox status of the tumor was measured using Tempol as a redox‑sensitive MRI contrast agent, and tumor hypoxia was measured with Oxo63, which is an oxygen-sensitive EPRI spin probe. "
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)